Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Taniguchi, Norio
NCT04825860: A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase	Terminated	2/3	83	Japan, RoW	SEP-363856 50 mg, SEP-363856 75 mg, Placebo	Sumitomo Pharma Co., Ltd.	Schizophrenia	10/23	10/23
Kawano, Masahiko
NCT04825860: A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase	Terminated	2/3	83	Japan, RoW	SEP-363856 50 mg, SEP-363856 75 mg, Placebo	Sumitomo Pharma Co., Ltd.	Schizophrenia	10/23	10/23